Population
Memory B cells from 3 healthy adult donors naturally infected with RSV
Design
Preclinical
Authors
Loading...
No immediate change to RSV prevention; leaves open new targets for human vaccine and mAb development.
Identification of highly potent RSV F-specific antibodies targeting a novel preF apex site provides new targets for RSV vaccine design and passive prophylaxis.
Gilman et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: